Study: Bekker 2024, New England Journal of Medicine

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

Citation

Bekker LG, Das M, Abdool Karim Q, Ahmed K et al (2024). New England Journal of Medicine. PubMed id 39046157.

Open on PubMed

Cards that cite this study (1)

Each card gives its own wording for who was tested, how and what was found.

  • HIV prevention, testing and PrEP Tier A strong

    A 5,338 HIV-negative adolescent girls and young women in South Africa and Uganda (n=5338)

    Phase 3 randomised, double-blind, controlled trial (PURPOSE 1) of twice-yearly lenacapavir, daily F/TAF or daily F/TDF.

    55 HIV infections occurred: none among 2,134 on lenacapavir (0 per 100 person-years; 95% CI 0.00 to 0.19), 39 among 2,136 on F/TAF (2.02) and 16 among 1,068 on F/TDF (1.69). Background incidence in the screened population was 2.41 per 100 person-years. Lenacapavir was significantly lower than background and than F/TDF; F/TAF did not differ significantly from background. The authors note gaps in uptake, adherence and persistence of PrEP among cisgender women.

    As recorded in this card: Bekker LG, Das M, Abdool Karim Q, Ahmed K et al (2024), New England Journal of Medicine, [primary]

    Note: African adolescent girls and young women; the abstract was cut off before safety and adherence details.

This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.